dactinomycin and granisetron

dactinomycin has been researched along with granisetron in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Akazawa, S; Inai, T; Kagawa, S; Kanayama, H; Naruo, S; Ogawa, I; Sakurai, N; Sumitani, H; Takigawa, H; Yokoseki, H1

Reviews

1 review(s) available for dactinomycin and granisetron

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for dactinomycin and granisetron

ArticleYear
[Efficacy of granisetron rescue therapy for nausea and vomiting induced by cancer chemotherapies in urogenital malignant tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:7

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Administration Schedule; Female; Granisetron; Humans; Male; Methotrexate; Middle Aged; Nausea; Urogenital Neoplasms; Vinblastine; Vomiting

1996

Other Studies

1 other study(ies) available for dactinomycin and granisetron

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004